Most recent by Robert Stott
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.
AGA stuck in neutral on AI-assisted colonoscopy guidance; ‘close tradeoff’ of cost/benefit
The AGA reported that it could not issue a recommendation for or against the use of computer-aided detection in colonoscopy due to “very low certainty of evidence” and “the close tradeoff between the desirable and undesirable effects.”
ACG unveils gastric premalignancy guidelines aligned with colon, esophagus surveillance
The ACG has released its first guidance for gastric premalignant conditions, such as atrophic gastritis, gastric intestinal metaplasia and dysplasia, in sync with surveillance recommendations established for the colon and esophagus.
US Multi-Society Task Force on CRC revamps colonoscopy bowel prep to set new ‘benchmark’
The U.S. Multi-Society Task Force on Colorectal Cancer has released updated guidance establishing a “reasonable benchmark” for the quality of bowel preparation prior to a colonoscopy exam.
VIDEO: ACG presidential roundtable explores ‘creative ways’ to tackle GI shortage
In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the looming threat of gastroenterology workforce shortage, alongside insights from a roundtable of ACG presidents on how we might still avoid it.
AGA urges antiviral prophylaxis for patients at high risk for hepatitis B reactivation
In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients receiving immunosuppressive therapy.
Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender
Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.
On-demand vonoprazan reduces nonerosive reflux disease symptoms ‘within first hour’
PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting.
‘High prevalence’ of extremity repetitive use injuries reported among endoscopists
PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting.
ELATIVE: Iqirvo ‘effective, well-tolerated treatment option’ for advanced-stage PBC
PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here.